[{"id":"d0cc18fc-dcf3-4b22-ba8d-fbfde5473a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT02884453","created_at":"2021-01-18T14:09:32.527Z","updated_at":"2024-07-02T16:36:55.626Z","phase":"Phase 2","brief_title":"Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma","source_id_and_acronym":"NCT02884453","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • MYC","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • MYC amplification • MYC amplification + HER-2 amplification","tags":["HER-2 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • MYC amplification • MYC amplification + HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 17","initiation":"Initiation: 07/19/2016","start_date":" 07/19/2016","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2019-09-18"}]